Interview with Dr. Josh Johnston of Georgia Eye Partners. Dr. Johnston shares with us his tips and tricks for successful Meibomian Gland Dysfunction (MGD) Treatment. We also highlight some exciting new therapies coming down the pipeline that have the potential to cause big changes in MGD treatment in the near future.
As a global specialized company dedicated to ophthalmology, Santen brings a 130-year history of scientific knowledge and organizational capabilities to research, development, and commercialization of pharmaceuticals, surgical and medical devices, and OTC eye-care products. Santen is the market leader for prescription ophthalmic pharmaceuticals in Japan, and its products now reach patients in more than 60 countries. Santen provides products and services to contribute to the well-being of patients, their loved ones, and consequently to society. For more information, please visit Santen’s websites www.santenusa.com and www.santen.com (Japan headquarters).
As a leading manufacturer of clinically proven and patented dry eye therapies, Eye Eco has helped thousands of practices across the country implement highly effective protocols for mild, moderate, and advanced MGD patients, as well as those suffering from Nocturnal Evaporative Stress. Eye Eco Inc. is California-based, locally owned, and 100% committed to developing innovations in the eye hydration field. Our goal is to bring long lasting relief to dry, irritated eyes through natural, effective products that improve the quality of patient’s lives, every single day.
Interview with Dr. Josh Johnston of Georgia Eye Partners. Dr. Johnston shares with us his tips and tricks for successful Meibomian Gland Dysfunction (MGD) Treatment. We also highlight some exciting new therapies coming down the pipeline that have the potential to cause big changes in MGD treatment in the near future.
